Molecular Vision: Maier, Mol Vis 2011; 17:1016-1023. Table 1

Table 1. Graft and patient data of all study patients.

Patient number	Patient age (years)	Gender	Indication	Risk profile	Postoperative treatment	Follow up (days)	IR
patient 1	63	f	FT	N	S	1320	no
patient 2	80	f	B	N	S	487	no
patient 3	21	m	K	N	S	1084	no
patient 4	20	m	K	N	S	594	no
patient 5	49	m	HSV	H	M	639	no
patient 6	30	m	K	N	S	261	yes
patient 7	88	f	U	H	S	554	no
patient 8	79	f	FT	N	S	219	yes
patient 9	80	f	B	N	S	49	no
patient 10	47	f	K	N	S	173	yes
patient 11	62	m	U	H	M	519	no
patient 12	62	f	F	N	S	538	no
patient 13	73	m	HSVT	H	M	235	yes
patient 14	71	m	F	N	S	342	yes
patient 15	84	f	U	H	M	142	no
patient 16	41	m	F	N	S	441	yes
patient 17	56	f	F	N	S	730	no
patient 18	77	m	F	N	S	213	yes
mean/% all	60.1	50%f	na	72%N	78%S	474	na
mean/% without IR	60.4	64%f	na	64%N	73%S	605	na
mean/% with IR	60.7	29%f	na	86%N	86%S	269	na

PK=penetrating keratoplasty, ECD=endothelial cell density, IR=immune reaction. Gender: f=female, m=male. Indications: B=bullous keratopathy, F=Fuchs’ endothelial dystrophy, K=keratoconus, U=acute corneal ulcer, HSV=herpes simplex virus keratitis, T=triple procedure means combined surgery of penetrating keratoplasty with cataract extraction and posterior chamber lens. Risk profile: n=normal risk, H=high risk (definition see section patients and methods). Postoperative treatment: S=standard as described in the methods section, M=mycophenolate mofetil for 6 months postoperatively. ND=not determined, na=not applicable. For patients with immune reactions the time of follow-up reflects the time point of the occurrence of an immune reaction.